TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: As TFE3 fusion tRCC has unique characteristics of transcription factor translocation, which may become a potential drug target, it is meaningful to explore promising therapeutic drugs for metastatic tRCC by employing PDOs.